Last reviewed · How we verify

NCT06833229: FDG Immun Comb

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Recruiting now Last updated 11 April 2025
What this trial tests

trial testing FDG-PET in Carcinoma, Non-Small-Cell Lung (NSCLC) in 200 participants. Currently enrolling.

Timeline
27 January 2022
Primary endpoint
27 May 2028
27 January 2031

Quick facts

Lead sponsorCentre Antoine Lacassagne
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date27 January 2022
Primary completion27 May 2028
Estimated completion27 January 2031
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Antoine Lacassagne — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell Lung (NSCLC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis of this prospective observational pilot study of diagnostic diagnostic performance is that, for patients with NSCLC treated with immunotherapy associated or not with chemotherapy, certain metabolic biomarkers on 18FDG PET scans allow early identification of treatment response (or lack of response to treatment) and optimize prediction of tumor response compared with current standards.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of FDG-PET

Trials testing the same drug.

Other recruiting trials for Carcinoma, Non-Small-Cell Lung (NSCLC)

Currently open trials in the same condition.

Other Centre Antoine Lacassagne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06833229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing